Circulating Tumor DNA Analysis in Blood for the Prediction of Treatment Response in Patientswith Advanced Non-Small Cell Lung Cancer

2022 ◽  
Author(s):  
Antonio Russo
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Treatment Response ◽  
Cell Lung Cancer ◽  
Dna Analysis ◽  
Circulating Tumor Dna ◽  
Small Cell ◽  
Small Cell Lung ◽  
Tumor Dna

scholarly journals P3.04-11 The Influence of Circulating Tumor DNA Analysis on Response to Immunotherapy in Non-Small Cell Lung Cancer (NSCLC)

2018 ◽  
Vol 13 (10) ◽  
pp. S925-S926
Author(s):  
R. Grinberg ◽  
L. Roisman ◽  
S. Geva ◽  
M. Lefterova ◽  
K. Quinn ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Dna Analysis ◽  
Circulating Tumor Dna ◽  
Small Cell ◽  
Small Cell Lung ◽  
Tumor Dna

scholarly journals Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non–small cell lung cancer: Analysis of over 8000 cases

Cancer ◽  
2020 ◽  
Vol 126 (14) ◽  
pp. 3219-3228 ◽  
Author(s):  
Philip C. Mack ◽  
Kimberly C. Banks ◽  
Carin R. Espenschied ◽  
Rebekah A. Burich ◽  
Oliver A. Zill ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Dna Analysis ◽  
Circulating Tumor Dna ◽  
Small Cell ◽  
Clinical Impact ◽  
Driver Mutations ◽  
Small Cell Lung ◽  
Tumor Dna

Duration of Targeted Therapy in Patients With Advanced Non–small-cell Lung Cancer Identified by Circulating Tumor DNA Analysis

2020 ◽  
Vol 21 (6) ◽  
pp. 545-552.e1
Author(s):  
Karen L. Reckamp ◽  
Tejas Patil ◽  
Kedar Kirtane ◽  
Thereasa A. Rich ◽  
Carin R. Espenschied ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Targeted Therapy ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Dna Analysis ◽  
Circulating Tumor Dna ◽  
Small Cell ◽  
Small Cell Lung ◽  
Tumor Dna

scholarly journals 67P The influence of circulating tumor DNA analysis on response to immunotherapy in non-small cell lung cancer (NSCLC)

2018 ◽  
Vol 13 (4) ◽  
pp. S35-S36
Author(s):  
R. Grinberg ◽  
L.C. Roisman ◽  
S. Geva ◽  
L. Soussan-Gutman ◽  
A. Dvir ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Dna Analysis ◽  
Circulating Tumor Dna ◽  
Small Cell ◽  
Small Cell Lung ◽  
Tumor Dna

scholarly journals Pan-cancer circulating tumor DNA detection in over 10,000 Chinese patients

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Yongliang Zhang ◽  
Yu Yao ◽  
Yaping Xu ◽  
Lifeng Li ◽  
Yan Gong ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Circulating Tumor Dna ◽  
Small Cell ◽  
Chinese Patients ◽  
Plasma Samples ◽  
Small Cell Lung ◽  
Pan Cancer ◽  
Tumor Dna

AbstractCirculating tumor DNA (ctDNA) provides a noninvasive approach to elucidate a patient’s genomic landscape and actionable information. Here, we design a ctDNA-based study of over 10,000 pan-cancer Chinese patients. Using parallel sequencing between plasma and white blood cells, 14% of plasma cell-free DNA samples contain clonal hematopoiesis (CH) variants, for which detectability increases with age. After eliminating CH variants, ctDNA is detected in 73.5% of plasma samples, with small cell lung cancer (91.1%) and prostate cancer (87.9%) showing the highest detectability. The landscape of putative driver genes revealed by ctDNA profiling is similar to that in a tissue-based database (R2 = 0.87, p < 0.001) but also shows some discrepancies, such as higher EGFR (44.8% versus 25.2%) and lower KRAS (6.8% versus 27.2%) frequencies in non-small cell lung cancer, and a higher TP53 frequency in hepatocellular carcinoma (53.1% versus 28.6%). Up to 41.2% of plasma samples harbor drug-sensitive alterations. These findings may be helpful for identifying therapeutic targets and combined treatment strategies.

Sign in / Sign up

Export Citation Format

Share Document